Mechanistic study of leukopenia treatment by Qijiao shengbai Capsule via the Bcl2/Bax/CASAPSE3 pathway
- PMID: 39295929
- PMCID: PMC11408280
- DOI: 10.3389/fphar.2024.1451553
Mechanistic study of leukopenia treatment by Qijiao shengbai Capsule via the Bcl2/Bax/CASAPSE3 pathway
Abstract
Background: Leukopenia can be caused by chemotherapy, which suppresses bone marrow function and can impact the effectiveness of cancer treatment. Qijiao Shengbai Capsule (QJSB) is commonly used to treat leukopenia, but the specific bioactive components and mechanisms of action are not well understood.
Objectives and results: This study aimed to analyze the active ingredients of QJSB and its potential targets for treating leukopenia using network pharmacology and molecular docking. Through a combination of serum pharmacochemistry, multi-omics, network pharmacology, and validation experiments in a murine leukopenia model, the researchers sought to understand how QJSB improves leukopenia. The study identified 16 key components of QJSB that act in vivo to increase the number of white blood cells in leukopenic mice. Multi-omics analysis and network pharmacology revealed that the PI3K-Akt and MAPK signaling pathways are important in the treatment of leukopenia with QJSB. Five specific targets (JUN, FOS, BCl-2, CASPAS-3) were identified as key targets.
Conclusion: Validation experiments confirmed that QJSB regulates genes related to cell growth and inhibits apoptosis, suggesting that apoptosis may play a crucial role in leukopenia development and that QJSB may improve immune function by regulating apoptotic proteins and increasing CD4+ T cell count in leukopenic mice.
Keywords: Leukopenia; Qijiao Shengbai Capsule; apoptosis; mitochondrial apoptosis; multi-omics.
Copyright © 2024 Jiang, Wang, Sun, Zhang, Zhang, Cao, Wang, Liu and Gao.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Qijiao Shengbai Capsule alleviated leukopenia by interfering leukotriene pathway: Integrated network study of multi-omics.Phytomedicine. 2024 Jun;128:155424. doi: 10.1016/j.phymed.2024.155424. Epub 2024 Feb 7. Phytomedicine. 2024. PMID: 38537441
-
Exploring the effects of Qijiao Shengbai capsule on leukopenic mice from the perspective of intestinbased on metabolomics and 16S rRNA sequencing.Heliyon. 2023 Sep 14;9(9):e19949. doi: 10.1016/j.heliyon.2023.e19949. eCollection 2023 Sep. Heliyon. 2023. PMID: 37810141 Free PMC article.
-
[Effective components and mechanism of Qijiao Shengbai Capsules based on fingerprinting and network pharmacology].Zhongguo Zhong Yao Za Zhi. 2023 Mar;48(6):1526-1534. doi: 10.19540/j.cnki.cjcmm.20221127.301. Zhongguo Zhong Yao Za Zhi. 2023. PMID: 37005840 Chinese.
-
EXPERIMENTAL STUDY OF CHEMOTHERAPY RELATED LEUKOCYTOPENIA TREATED BY VARIOUS PEROAL LEUCOCYTE INCREASING DRUGS.Afr J Tradit Complement Altern Med. 2016 Nov 23;14(1):155-164. doi: 10.21010/ajtcam.v14i1.17. eCollection 2017. Afr J Tradit Complement Altern Med. 2016. PMID: 28480393 Free PMC article.
-
Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation.Front Immunol. 2023 Sep 20;14:1235575. doi: 10.3389/fimmu.2023.1235575. eCollection 2023. Front Immunol. 2023. PMID: 37799727 Free PMC article.
References
-
- Bertelsen L. B., Shen Y. Y., Nielsen T., Stødkilde-Jørgensen H., Lloyd G. K., Siemann D. W., et al. (2011). Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. Int. J. Radiat. Biol. 87 (11), 1126–1134. 10.3109/09553002.2011.605418 - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous